U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07633951) titled 'Multicenter Epidemiological Study for the Evaluation of the Seroprevalence of Total and Neutralizing Antibodies Against Adenoassociated Virus Serotypes Used in Gene Therapy in Patients With Neuromuscular Diseases of Genetic Origin.' on May 26.
Brief Summary: This study aims to assess the overall seroprevalence of neutralizing antibodies against different AAVs potentially used in gene therapy in patients with genetic neuromuscular diseases.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Neuromuscular Deficits
Genetic Disorder
Intervention:
DIAGNOSTIC_TEST: Dosage of AAV neutralizing antibodies
In each clinical ...